Stay updated on SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial
Sign up to get notified when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.
Latest updates to the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page
- Check5 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.3%
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedA new study has been added, now totaling 52 studies, with details about a recruiting site in Tampa, Florida, including contact information for the principal investigator.SummaryDifference0.7%
- Check26 days agoChange DetectedA new study has been added, increasing the total to 51, with details about recruitment at the Children's Hospital of Michigan, while the previous study has been removed, updating the revision from v2.10.0 to v2.10.2.SummaryDifference0.9%
- Check33 days agoChange DetectedA new phase II trial has been added to evaluate the safety and efficacy of revumenib in combination with chemotherapy for infants and young children with relapsed or refractory KMT2A-rearranged leukemia, replacing the previous study that referred to SNDX-5613.SummaryDifference10%
- Check40 days agoChange DetectedDifference0.1%
- Check42 days agoChange DetectedDifference0.1%
Stay in the know with updates to SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.